ADIPOPHARMA

We are a French biotech company committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis... We are developing PATAS, a unique first-in-class insulin sensitizer that targets the adipocyte and that will treat insulin resistance, type 2 diabetes and associated comorbidities.

Also known as: AdipoPharma LLC, AdipoPharma SAS, AdipoPharma SRL

Primary location: Strasbourg France